JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.